Neurocrine sees August FDA action date for valbenazine for chorea
Neurocrine Biosciences (NASDAQ:NBIX) noted that its supplemental New Drug Application for valbenazine as a treatment for chorea associated with Huntington's disease has an Aug. 20 FDA action date.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.